N-aroylanthranilic acids and derivatives as inhibitors of bacterial class B transpeptidases

Description:

Technology: MUSC inventors identified a new chemical scaffold (N-aroylanthranilic acids and derivatives) as inhibitors of various class B penicillin-binding proteins (PBPs). The novel molecules showed high potency of PBP inhibition. Antimicrobial assays against antibiotic-resistant gonorrhea strain FA19 and H041 showed significant growth inhibition at the µM level.

 

Figure 1: Activity data for compound 1. A. PBP inhibition was determined in a purified protein assay in which a given PBP was preincubated with 100 μM compound, followed by addition of 1 μM Bocillin-FL. Data are presented as a fraction of DMSO control. B. Antimicrobial activity was determined in a disc diffusion assay against susceptible reference gonococcal strain FA19 and multi-drug resistant H041 at 10 μg per disc. Data for a ceftriaxone control disc (CRO) are shown.

 

Data showed compound 1 inhibited PBP activity when incubated with truncated PBP2 and PBP3 (Figure 1A). The compound also inhibited growth rate significantly in antibiotic-resistant strains FA19 and H041 (Figure 1B). To further optimize potency, compound 1 derivatives were generated. Ten compound 1 derivatives were found to inhibit PBP activity at 10 µM, and the compounds also reduced the bacterial growth at 10 µg level (Figure 2).

 

Figure 2: Inhibition data for representative compound 1 derivatives against tPBP2H041 at 10 μM. Values were determined in a purified protein assay in which tPBP2H041 was preincubated with 10 μM compound, followed by addition of 1 μM Bocillin-FL. Data are presented as a fraction of activity of the DMSO control. Disc diffusion data for potent representative compound 1 derivatives against N. gonorrhoeae FA19 and H041. Compounds were tested against susceptible reference gonococcal strain FA19 and multi-drug resistant H041 at 10 μg per disc. Data for a ceftriaxone control disc (CRO) are shown.

 

In summary, the novel compounds showed a promising inhibitory effect on PBP activity and the growth of antibiotic-resistant gonorrhea, which could also translate to other pathogenic bacteria.

 

Overview: β-lactams (penicillins, cephalosporins, and carbapenems) are the most widely used antibiotics. At the molecular level, β-lactams target the transpeptidase activity of penicillin-binding proteins (PBPs) that are involved in bacterial cell-wall biosynthesis, resulting in bacterial death. However, several gram-negative bacteria have acquired resistance to the antibiotics due to the production of a specific B-lactams hydrolase, presence of low-affinity PBPS, and active expulsion of B-lactams via efflux pumps. There is an unmet need to develop new antibiotics to overcome the treatment of bacterial infection.

 

Applications:  Antibiotics, Bacterial infection

 

Advantages:  The novel class of antibiotics inhibits the gram-negative bacterial that have resistance to the current antibiotics.

 

Key Words: Antibiotics, antibiotic-resistant Neisseria gonorrhoeae, bacterial infection

 

Inventors:  Patrick Woster, Christopher Davies, Jonathan Turner, Joy Kirkpatrick

       

Patent Status:        Provisional filed on 6/15/2020

              

MUSC-FRD Technology ID: P20148

 

Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Admin/archive
MUSC Foundation for Research Development
843-876-1900
 
Inventors:
Jonathan Turner
Christopher Davies
Patrick Woster
Joy Kirkpatrick
Keywords:
© 2021. All Rights Reserved. Powered by Inteum